We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts Healthcare (MDRX) Posts In-Line Earnings in Q2
Read MoreHide Full Article
Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) reported second-quarter 2016 earnings of 10 cents per share, which was in line with the Zacks Consensus Estimate. The figure improved 25% on a year-over-year basis.
The upside was driven by 12.8% growth in revenues (including deferred revenues and other adjustments), which totaled $396.6 million, slightly ahead of the Zacks Consensus Estimate of $396 million.
Quarter Details
According to management, software delivery revenues in the quarter increased 11%, totaling $258 million. Notably, recurring software revenues increased 10% and nonrecurring software revenues increased 15%.
At the Client services segment, revenues surged 16% to $139 million, with 31% growth in recurring revenues. However, exclusive of Netsmart, recurring revenues at this section improved 13%.
Bookings increased 39% year over year to $362 million on the back of the acquisition of Netsmart. However, excluding the contribution by Netsmart, bookings totaled $318 million, up 22% from the prior-year quarter. Notably, software delivery bookings grew 49%, while service bookings increased 26% on a year-over-year basis.
Current backlog at Allscripts stands at $4 billion, an increase of $443 million from the year-ago quarter. The upside was mainly driven by a significant number of bookings in the reported quarter. We note that Netsmart contributed a major $267 million toward the backlog.
Meanwhile, contract revenue backlog as of Jun 30, 2016, totaled $4.0 billion, an increase of $443 million from the figure as of Mar 31, 2016.
Allscripts signed a 10-year agreement with OptumCare, part of Optum and UnitedHealth Group. As per the deal, the latter can utilize the Allscipts TouchWorks suite as its electronic health record and practice management solution.
Allscripts also completed the previously announced transaction that combines Allscripts Homecare business with Netsmart in the reported quarter.
Margin Details
Adjusted gross margin expanded 400 basis points (bps) on a year-over-year basis to 48.1%, mainly driven by strong one-time software revenues. However, Netsmart did not particularly affect gross margins.
Operating expenses rose 15% year over year to $133 million owing to additional expenses associated with the consolidation of Netsmart.
Notably, adjusted EBITDA increased to $78 million in the reported quarter, a 26% rise from the second-quarter 2015 figure.
Guidance
For full-year 2016 revenues, Allscripts affirmed its guidance at the range of $1.580 billion to $1.610 billion.
Allscripts reiterated its adjusted earnings guidance at 55 cents to 62 cents per share.
Adjusted EBITDA is anticipated in the band of $280–$300 million.
Zacks Rank & Key Picks
Currently, Allscripts has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector are Natus Medical Inc , Mesa Laboratories Inc. (MLAB - Free Report) and Masimo Corporation (MASI - Free Report) . All the three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Allscripts Healthcare (MDRX) Posts In-Line Earnings in Q2
Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) reported second-quarter 2016 earnings of 10 cents per share, which was in line with the Zacks Consensus Estimate. The figure improved 25% on a year-over-year basis.
The upside was driven by 12.8% growth in revenues (including deferred revenues and other adjustments), which totaled $396.6 million, slightly ahead of the Zacks Consensus Estimate of $396 million.
Quarter Details
According to management, software delivery revenues in the quarter increased 11%, totaling $258 million. Notably, recurring software revenues increased 10% and nonrecurring software revenues increased 15%.
At the Client services segment, revenues surged 16% to $139 million, with 31% growth in recurring revenues. However, exclusive of Netsmart, recurring revenues at this section improved 13%.
Bookings increased 39% year over year to $362 million on the back of the acquisition of Netsmart. However, excluding the contribution by Netsmart, bookings totaled $318 million, up 22% from the prior-year quarter. Notably, software delivery bookings grew 49%, while service bookings increased 26% on a year-over-year basis.
Current backlog at Allscripts stands at $4 billion, an increase of $443 million from the year-ago quarter. The upside was mainly driven by a significant number of bookings in the reported quarter. We note that Netsmart contributed a major $267 million toward the backlog.
Meanwhile, contract revenue backlog as of Jun 30, 2016, totaled $4.0 billion, an increase of $443 million from the figure as of Mar 31, 2016.
ALLSCRIPTS HLTH Price, Consensus and EPS Surprise
ALLSCRIPTS HLTH Price, Consensus and EPS Surprise | ALLSCRIPTS HLTH Quote
Business Highlights
Allscripts signed a 10-year agreement with OptumCare, part of Optum and UnitedHealth Group. As per the deal, the latter can utilize the Allscipts TouchWorks suite as its electronic health record and practice management solution.
Allscripts also completed the previously announced transaction that combines Allscripts Homecare business with Netsmart in the reported quarter.
Margin Details
Adjusted gross margin expanded 400 basis points (bps) on a year-over-year basis to 48.1%, mainly driven by strong one-time software revenues. However, Netsmart did not particularly affect gross margins.
Operating expenses rose 15% year over year to $133 million owing to additional expenses associated with the consolidation of Netsmart.
Notably, adjusted EBITDA increased to $78 million in the reported quarter, a 26% rise from the second-quarter 2015 figure.
Guidance
For full-year 2016 revenues, Allscripts affirmed its guidance at the range of $1.580 billion to $1.610 billion.
Allscripts reiterated its adjusted earnings guidance at 55 cents to 62 cents per share.
Adjusted EBITDA is anticipated in the band of $280–$300 million.
Zacks Rank & Key Picks
Currently, Allscripts has a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader medical sector are Natus Medical Inc , Mesa Laboratories Inc. (MLAB - Free Report) and Masimo Corporation (MASI - Free Report) . All the three stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>